NovaTests
The first predictive test for radio-sensitivity. A step towards an improved and personalised radiation therapy cancer treatment.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0NovaTests project word cloud
Explore the words cloud of the NovaTests project. It provides you a very rough idea of what is the project "NovaTests" about.
Project "NovaTests" data sheet
The following table provides information about the project.
| Coordinator |
NOVAGRAY
Organization address contact info |
| Coordinator Country | France [FR] |
| Project website | http://www.nova-gray.com |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-05-01 to 2018-09-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | NOVAGRAY | FR (MONTPELLIER) | coordinator | 50˙000.00 |
Map
Project objective
Each year, two out of three cancer patients undergo radiation therapy, meaning close to 1.5M patients in Europe and 2M in the US. However, scientific evidences prove a direct link between radiation therapy and several serious late effects. This because patient’s tolerance to radiation vary significantly and radiotherapy affects indiscriminately both healthy and cancer cells, damaging also active working cells, tissues or organs around the tumour. There is, therefore, an unmet clinical need to tailor treatments to each patient’s unique biology. NovaTests are the first predictive radio-sensitivity tests for cancer treatment. By analysing a simple blood sample, in one week time, we can determine with high accuracy (over 90%) not only whether a patient is sensitive or not to radiation but also how sensitive the patient is. We allow for more efficient treatments and improved quality of cancer survivors, not only during radiation treatments but for the rest of their lives. Our first test, the NovaGray Breast® is aimed at measuring radiosensitivity for breast cancer patients. It meets all regulatory requirements of the 98/79 directive pertaining to the in-vitro diagnostic medical devices, has been stamped with the CE marking in February 2016. So far, €0.5M million have been invested into the development and testing of technology to ensure its robustness and efficiency and move into the next stage of tests development and validation. Within the overall project, we intend to scale-up the process by automating it and run a multi-centre clinical trial to validate the reliability of the test. Further ongoing developments include the extension of the technology to prostate and lung cancers. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of NovaTests and their market uptake.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVATESTS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NOVATESTS" are provided by the European Opendata Portal: CORDIS opendata.